KBC Group
SPRO icon

KBC Group’s Spero Therapeutics SPRO Stock Holding History

KBC Group’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-6,935
Closed -$80K – 1500
2019
Q2 		$80K Hold
6,935
– – ﹤0.01% 1324
2019
Q1 		$89K Hold
6,935
– – ﹤0.01% 1282
2018
Q4 		$43K Hold
6,935
– – ﹤0.01% 1228
2018
Q3 		$73K Buy
+6,935
New +$80.5K ﹤0.01% 1309

Other funds holding SPRO

AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

KBC Group's SPRO Position: Q3 2019 in Review

KBC Group sold out of Spero Therapeutics (SPRO) in Q3 2019, closing a stake of 6,935 shares — an estimated $80K sold.

KBC Group first reported a position in SPRO in Q3 2018 and held it in 4 quarters. The position peaked at $89K in Q1 2019. 59 funds tracked by Wall St. Rank hold SPRO as of Q3 2019.

  • KBC Group reported no remaining Spero Therapeutics position as of Q3 2019 after selling out during the quarter.
  • KBC Group sold 6,935 Spero Therapeutics shares in Q3 2019, an estimated $80K.
  • KBC Group first reported a position in Spero Therapeutics in Q3 2018 and held it in 4 quarters.
  • KBC Group's Spero Therapeutics position peaked at $89K in Q1 2019.
  • 59 funds tracked by Wall St. Rank held Spero Therapeutics as of Q3 2019.

Based on KBC Group's 13F filing for Q3 2019, filed 7 Nov 2019.